Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $42.00 at Truist Financial

Collegium Pharmaceutical (NASDAQ:COLL) had its price target raised by Truist Financial from $40.00 to $42.00 in a report issued on Friday, Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other research firms also recently commented on COLL. StockNews.com downgraded Collegium Pharmaceutical from a strong-buy rating to a buy rating in a report on Wednesday, May 1st. Needham & Company LLC reissued a hold rating on shares of Collegium Pharmaceutical in a research report on Friday. Jefferies Financial Group raised Collegium Pharmaceutical from a hold rating to a buy rating and upped their target price for the company from $41.00 to $44.00 in a research report on Friday, June 7th. Piper Sandler reissued a neutral rating and issued a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday. Finally, HC Wainwright raised Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 target price for the company in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of Moderate Buy and an average target price of $42.00.

Collegium Pharmaceutical Stock Up 0.5 %

NASDAQ COLL traded up $0.18 during trading hours on Friday, hitting $35.50. 413,104 shares of the company were exchanged, compared to its average volume of 471,066. The company has a 50 day moving average of $33.09 and a two-hundred day moving average of $34.84. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. Collegium Pharmaceutical has a 52-week low of $20.95 and a 52-week high of $40.95. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 14.79 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same quarter in the prior year, the business posted $1.13 EPS. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. Equities research analysts anticipate that Collegium Pharmaceutical will post 5.73 earnings per share for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Garen G. Bohlin sold 28,985 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the completion of the sale, the director now directly owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,502 shares of company stock valued at $3,540,796. 3.98% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after buying an additional 113,300 shares during the period. Dimensional Fund Advisors LP increased its stake in Collegium Pharmaceutical by 2.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company’s stock valued at $33,457,000 after purchasing an additional 19,876 shares in the last quarter. BOKF NA purchased a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $490,000. American Century Companies Inc. increased its stake in Collegium Pharmaceutical by 8.8% in the 2nd quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock valued at $3,214,000 after purchasing an additional 8,097 shares in the last quarter. Finally, Choreo LLC purchased a new position in Collegium Pharmaceutical in the 2nd quarter valued at approximately $396,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.